Stockscreener 앱 받기
1.485
3.57%
-0.055
시장 영업 전:
1.59
0.105
+7.07%
전일 마감가:
$1.54
열려 있는:
$1.52
하루 거래량:
547.97K
Relative Volume:
0.41
시가총액:
$89.58M
수익:
-
순이익/손실:
$-27.37M
주가수익비율:
-3.2623
EPS:
-0.4552
순현금흐름:
$-25.99M
1주 성능:
-2.30%
1개월 성능:
-6.01%
6개월 성능:
-72.80%
1년 성능:
-74.66%
1일 변동 폭
$1.48
$1.56
1주일 범위
$1.4601
$1.581
52주 변동 폭
$1.07
$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.485 | 90.49M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - Vinanet
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aldeyra Therapeutics Inc (ALDX) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - accessnewswire.com
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results - marketbeat.com
Aldeyra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary - TradingView
Aldeyra Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
INVESTOR DEADLINE APPROACHING: Aldeyra Therapeutics (ALDX) Invest - The National Law Review
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics Leases New Concord Headquarters Space - The Globe and Mail
Aldeyra Therapeutics, Inc. Signs Lease for New Corporate Headquarters in Concord, Massachusetts - marketscreener.com
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Sahm
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G - Stock Titan
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aldeyra Therapeutics Inc (ALDX) Cash Flow - TradingKey
Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX - TradingView
ALDX|Aldeyra Therapeutics Inc|Price:1.580|Chg%:+0.060 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aldeyra Therapeutics Inc (ALDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALDX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Revenue per share of Aldeyra Therapeutics, Inc. – FWB:137 - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out | NDAQ:ALDX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission - TradingView
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aldeyra Therapeutics Inc 주식 (ALDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
8.37%
0.23%
자본화:
|
볼륨(24시간):